Experts highlight ten common requests received in their Gastroenterology advice and guidance service and explain how these ...

Discover a recent study presented at EASL 2025 that explored the impact of opt-out testing for blood-borne viruses in ...

Functional cure, defined as durable hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA titers below the lower limit of detection (LLOD), is associated with better clinical outcomes of ...

Q1 2025 Earnings Call Transcript May 6, 2025 Dynavax Technologies Corporation misses on earnings expectations. Reported EPS is $0.01 EPS, expectations were $0.03. Operator: Good day ladies and ...

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2025, along with recent ...

BRIUMVI U.S. net revenue of $119.7 million. Raises full year 2025 global net revenue target to approximately $575 million and raises full year BRIUMVI U.S. net ...

Q1 2025 Earnings Conference Call April 30, 2025 7:00 AM ETCompany ParticipantsConstantin Fest - Head of IREmma Walmsley - CEOLuke Miels ...

Patients with current or past infection with the hepatitis B virus ... surface antigen (HBsAg) and core antibody (anti-HBcAb) prior to initiating immunosuppression, and recommend antiviral prophylaxis ...